BRIEF—Celgene hopes to impress with progress on investigational and approved therapies

The Bristol-Myers Squibb target Celgene could be about to present data at the American Society of Clinical Oncology annual meeting for the final time as an independent company, and it could be an impressive showing.

Data from more than 40 company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene’s investigational and approved therapies will be presented.

The US biotech will present new sub-group analyses from the multicenter, Phase I TRANSCEND NHL 001 study evaluating the investigational therapy lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell product, in adult patients with relapsed/refractory non-Hodgkin’s lymphoma who have secondary CNS lymphoma. There will also be new data from the multicenter, Phase I/II TRANSCEND CLL 004 trial in adult patients with relapsed/refractory chronic lymphocytic leukemia.

Abstracts will also highlight investigational therapies or new uses for approved therapies in the treatment of myelofibrosis, multiple myeloma and pancreatic cancer.